These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 27333728)

  • 41. Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.
    Cohen M; Maillart E; Tourbah A; De Sèze J; Vukusic S; Brassat D; Anne O; Wiertlewski S; Camu W; Courtois S; Ruet A; Debouverie M; Le Page E; Casez O; Heinzlef O; Stankoff B; Bourre B; Castelnovo G; Rico A; Berger E; Camdessanche JP; Defer G; Clavelou P; Al Khedr A; Zephir H; Fromont A; Papeix C; Brochet B; Pelletier J; Lebrun C;
    JAMA Neurol; 2014 Apr; 71(4):436-41. PubMed ID: 24566807
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study.
    Baldi E; Guareschi A; Vitetta F; Senesi C; Curti E; Montepietra S; Simone AM; Immovilli P; Caniatti L; Tola MR; Pesci I; Montanari E; Sola P; Granella F; Motti L; Ferraro D
    Curr Med Res Opin; 2014 Sep; 30(9):1849-55. PubMed ID: 24831186
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preapproval and postapproval evidence on drugs for multiple sclerosis.
    Gerardi C; Bertele' V; Rossi S; Garattini S; Banzi R
    Neurology; 2018 May; 90(21):964-973. PubMed ID: 29695598
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
    J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Development of new therapies for multiple sclerosis].
    Holmøy T; Celius EG
    Tidsskr Nor Laegeforen; 2011 May; 131(8):832-6. PubMed ID: 21556088
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Emerging therapies in relapsing-remitting multiple sclerosis.
    Marriott JJ; O'Connor PW
    Rev Recent Clin Trials; 2010 Sep; 5(3):179-88. PubMed ID: 20500147
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Multiple sclerosis: beyong first line therapies].
    Schluep M; Du Pasquier R
    Rev Med Suisse; 2012 May; 8(339):946-9. PubMed ID: 22675826
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pregnancy and Multiple Sclerosis: An Update on the Disease Modifying Treatment Strategy and a Review of Pregnancy's Impact on Disease Activity.
    Varytė G; Zakarevičienė J; Ramašauskaitė D; Laužikienė D; Arlauskienė A
    Medicina (Kaunas); 2020 Jan; 56(2):. PubMed ID: 31973138
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current and future disease-modifying therapies in multiple sclerosis.
    Lim SY; Constantinescu CS
    Int J Clin Pract; 2010 Apr; 64(5):637-50. PubMed ID: 20456216
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Neuroprotection in the treatment of multiple sclerosis].
    Zipp F; Gold R
    Nervenarzt; 2011 Aug; 82(8):973-7. PubMed ID: 21761185
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options.
    Disanto G; Benkert P; Lorscheider J; Mueller S; Vehoff J; Zecca C; Ramseier S; Achtnichts L; Findling O; Nedeltchev K; Radue EW; Sprenger T; Stippich C; Derfuss T; Louvion JF; Kamm CP; Mattle HP; Lotter C; Du Pasquier R; Schluep M; Pot C; Lalive PH; Yaldizli Ö; Gobbi C; Kappos L; Kuhle J;
    PLoS One; 2016; 11(3):e0152347. PubMed ID: 27032105
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.
    Huhn K; Bayas A; Doerck S; Frank B; Gerbershagen K; Hellwig K; Kallmann B; Kleinschnitz C; Kleiter I; Lee DH; Limmroth V; Mäurer M; Meuth S; Rieckmann P; Ruck T; Gold R; Linker RA
    J Neurol; 2018 Jul; 265(7):1521-1527. PubMed ID: 29696498
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Potential neuroprotective effect of Fingolimod in multiple sclerosis and its association with clinical variables.
    Pitteri M; Magliozzi R; Bajrami A; Camera V; Calabrese M
    Expert Opin Pharmacother; 2018 Mar; 19(4):387-395. PubMed ID: 29397790
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Melanoma during fingolimod treatment for multiple sclerosis.
    Velter C; Thomas M; Cavalcanti A; Bastien M; Chochon F; Lubetzki C; Routier E; Robert C
    Eur J Cancer; 2019 May; 113():75-77. PubMed ID: 30986706
    [No Abstract]   [Full Text] [Related]  

  • 57. The future of multiple sclerosis treatments.
    Coclitu C; Constantinescu CS; Tanasescu R
    Expert Rev Neurother; 2016 Dec; 16(12):1341-1356. PubMed ID: 27682738
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tumefactive demyelinating lesions: A comprehensive review.
    Algahtani H; Shirah B; Alassiri A
    Mult Scler Relat Disord; 2017 May; 14():72-79. PubMed ID: 28619436
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Epidemiology of Pharmacological Treatment of Multiple Sclerosis in Croatia.
    Tomasović S; Košćak Lukač J; Sremec J; Klepac N; Draganić P; Bielen I
    Psychiatr Danub; 2021 Dec; 33(Suppl 13):204-208. PubMed ID: 35150487
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis.
    Fox EJ; Rhoades RW
    Curr Opin Neurol; 2012 Feb; 25 Suppl():S11-9. PubMed ID: 22398660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.